Insider Transaction and Recent Performance of Ani Pharmaceuticals
Stephen P. Carey, Senior Vice President and Chief Financial Officer of Ani Pharmaceuticals Inc. (NASDAQ:ANIP), executed a pre‑arranged Rule 10b5‑1 trading plan that was adopted on March 6, 2026. Under this plan, he exercised stock options to acquire 3,313 shares of ANI common stock at an exercise price of $49.51 per share, resulting in a total outlay of $164,026. Immediately thereafter, on July 2, 2026, he disposed of the same 3,313 shares in the open market at $86.00 per share, generating gross proceeds of $284,918. The net gain from the combined exercise and sale is approximately $120,892.
The option grant follows a vesting schedule in which 25 % of the total options vested on each of March 31, 2018; March 31, 2019; March 31, 2020; and March 31, 2021, with the entire award set to expire on March 30, 2027. Following the July 2 transaction, Mr. Carey’s direct holding in ANI Pharmaceuticals stands at 177,543 shares.
At the time of the sale, ANI Pharmaceuticals’ share price was trading near $85.05, reflecting a 31 % total return over the preceding year. The company’s market capitalization is approximately $1.8 billion, and it trades at a price‑to‑earnings multiple of 21.78. InvestingPro’s analysis suggests the stock is undervalued relative to its fair value, placing it among the most undervalued stocks in its coverage universe.
In parallel, ANI Pharmaceuticals reported its first‑quarter 2026 financial results, which surpassed analyst expectations. The company posted earnings per share of $2.05, representing a 41.38 % increase over the consensus forecast of $1.45. Revenue for the quarter was $237.5 million, exceeding the projected $213.42 million. No analyst upgrades or downgrades were disclosed in conjunction with the results, but the earnings and revenue beat indicate a positive market sentiment toward the firm.
---